1 active not recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
Follow Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor: new trials by email Literature Review of Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor trials Research Report on Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Adavosertib, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 124 | 2014-07-21 | 2026-09-10 |
Brenner Tumor (1) · Fallopian Tube Neoplasms (1) · Neoplasms (1) · Ovarian Neoplasms (1)
Adnexal Diseases (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Fallopian Tube Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Gonadal Disorders (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Connective Tissue (1) · Neoplasms, Connective and Soft Tissue (1) · Neoplasms, Fibroepithelial (1)
Gemcitabine (1) · adavosertib (1)
National Cancer Institute (NCI) (1)
Canada (1) · Singapore (1) · United States (1)
Amit M Oza (1)
N01CM00032 (1), N01CM00038 (1), N01CM00071 (1), U10CA180821 (1), UM1CA186644 (1), UM1CA186705 (1)